Anna Gluskin, Chairman and CEO of Generex Biotechnology Corporation, presides over the closing bell.

Wednesday May 2, 2007

Generex Biotechnology Corporation
[GNBT]

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 05/02/2007 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Anna Gluskin, Chairman and CEO of Generex Biotechnology Corporation, presides over the closing bell. Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at Jolene.Libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission. © Copyright 2007, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.